Kai Chu
About
Kai Chu is a scholar working on Infectious Diseases, Epidemiology and Cardiology and Cardiovascular Medicine.
According to data from OpenAlex, Kai Chu has authored 49 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Infectious Diseases, 19 papers in Epidemiology and 11 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Kai Chu's work include Viral gastroenteritis research and epidemiology (13 papers), SARS-CoV-2 and COVID-19 Research (13 papers) and Viral Infections and Immunology Research (11 papers). Kai Chu is often cited by papers focused on Viral gastroenteritis research and epidemiology (13 papers), SARS-CoV-2 and COVID-19 Research (13 papers) and Viral Infections and Immunology Research (11 papers). Kai Chu collaborates with scholars based in China, United States and Taiwan. Kai Chu's co-authors include Fengcai Zhu, Jingxin Li, Hongxing Pan, Weidong Yin, Gang Zeng, Changgui Li, Rong Tang, Yuansheng Hu, Weixiao Han and Yan Song and has published in prestigious journals such as The Lancet, Nature Communications and PLoS ONE.
In The Last Decade
Kai Chu
45 papers receiving 1.8k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Kai Chu China | 16 | 1.4k | 424 | 277 | 249 | 218 | 49 | 1.8k | ||
| Weidong Yin China | 14 | 1.8k 1.3× | 498 1.2× | 299 1.1× | 642 2.6× | 442 2.0× | 30 | 2.4k | ||
| Nasamon Wanlapakorn Thailand | 21 | 829 0.6× | 213 0.5× | 509 1.8× | 270 1.1× | 148 0.7× | 106 | 1.4k | ||
| Yuansheng Hu China | 12 | 1.0k 0.7× | 326 0.8× | 187 0.7× | 144 0.6× | 255 1.2× | 27 | 1.4k | ||
| Penny M. Heaton United States | 25 | 1.3k 0.9× | 160 0.4× | 382 1.4× | 655 2.6× | 118 0.5× | 41 | 1.7k | ||
| Edward P K Parker United Kingdom | 14 | 683 0.5× | 143 0.3× | 164 0.6× | 264 1.1× | 209 1.0× | 48 | 977 | ||
| Yoon‐Seok Chung South Korea | 16 | 1.1k 0.8× | 59 0.1× | 392 1.4× | 107 0.4× | 317 1.5× | 69 | 1.9k | ||
| Irja Davidkin Finland | 25 | 890 0.6× | 670 1.6× | 1.4k 4.9× | 93 0.4× | 60 0.3× | 43 | 2.0k | ||
| Steven G. F. Wassilak United States | 28 | 1.2k 0.9× | 398 0.9× | 1.2k 4.3× | 1.0k 4.1× | 92 0.4× | 50 | 2.5k | ||
| Lin Cui Singapore | 21 | 1.0k 0.7× | 128 0.3× | 773 2.8× | 50 0.2× | 282 1.3× | 49 | 2.0k | ||
| Steven G.F. Wassilak United States | 33 | 1.7k 1.2× | 500 1.2× | 1.1k 4.1× | 1.4k 5.8× | 109 0.5× | 73 | 3.0k |
Countries citing papers authored by Kai Chu
Since
Specialization
Citations
This map shows the geographic impact of Kai Chu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kai Chu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kai Chu more than expected).
Fields of papers citing papers by Kai Chu
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Kai Chu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kai Chu. The network helps show where Kai Chu may publish in the future.
Co-authorship network of co-authors of Kai Chu
This figure shows the co-authorship network connecting the top 25 collaborators of Kai Chu. A scholar is included among the top collaborators of Kai Chu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kai Chu. Kai Chu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Zhang, Yang, et al.. (2025). Immunogenicity and safety of a live attenuated varicella vaccine in children aged 1 to 12 years: A double-blind, randomized, parallel-controlled phase III clinical trial in China. Human Vaccines & Immunotherapeutics. 21(1). 2452681–2452681.
2.
Han, Xu, Hongxing Pan, Pengfei Jin, et al.. (2024). A head-to-head comparison of humoral and cellular immune responses of five COVID-19 vaccines in adults in China. Frontiers in Immunology. 15. 1455730–1455730.
3.
Hu, Wenjing, Yang Wang, Kai Chu, et al.. (2024). Nasal Staphylococcus aureus Carriage and Antimicrobial Resistance Profiles Among Community-Dwelling Adults in Jiangsu, China. Infectious Diseases and Therapy. 13(6). 1215–1233.
4.
Hu, Jialei, Yueyue Liu, Shuo Liu, et al.. (2023). Safety and immunogenicity of a modified Omicron-adapted inactivated vaccine in healthy adults: a randomized, double-blind, active-controlled Phase III clinical trial. Frontiers in Immunology. 14. 1241153–1241153.
5.
Chu, Kai, Yuemei Hu, Hongxing Pan, et al.. (2023). A randomized, open-label, phase 3 study evaluating safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in Chinese infants and children under 6 years of age. Human Vaccines & Immunotherapeutics. 19(2). 2235926–2235926.
6.
Liang, Zihao, Xudong Zheng, Yuan Wang, Kai Chu, & Yanan Gao. (2023). Using system biology and bioinformatics to identify the influences of COVID-19 co-infection with influenza virus on COPD. Functional & Integrative Genomics. 23(2). 175–175.
7.
Xin, Qianqian, Qianhui Wu, Xinhua Chen, et al.. (2022). Six-month follow-up of a booster dose of CoronaVac in two single-centre phase 2 clinical trials. Nature Communications. 13(1). 3100–3100.
8.
Liu, Jiankai, Baoying Huang, Yafei Liu, et al.. (2021). Immunogenicity and Safety of a 3-Dose Regimen of a SARS-CoV-2 Inactivated Vaccine in Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. The Journal of Infectious Diseases. 225(10). 1701–1709.
9.
Zeng, Gang, Qianhui Wu, Hongxing Pan, et al.. (2021). Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. The Lancet Infectious Diseases. 22(4). 483–495.
10.
Chu, Kai, Kangwei Xu, Rong Tang, et al.. (2020). Immunogenicity and safety of an inactivated quadrivalent influenza vaccine: A randomized, double-blind, controlled phase III study in healthy population aged ≥3 years. Vaccine. 38(37). 5940–5946.
11.
Wu, Hannah, Zhiqiang Fu, Lu Ke, et al.. (2017). Vaccination with recombinant paramyosin in Montanide ISA206 protects against Schistosoma japonicum infection in water buffalo. Vaccine. 35(26). 3409–3415.
12.
Wei, Mingwei, Fanyue Meng, Shiyuan Wang, et al.. (2016). 2-Year Efficacy, Immunogenicity, and Safety of Vigoo Enterovirus 71 Vaccine in Healthy Chinese Children: A Randomized Open-Label Study. The Journal of Infectious Diseases. 215(1). 56–63.
13.
Liu, Wenyu, Feixue Wei, Jie Tang, et al.. (2016). [Detection of neutralizing antibodies and DNA of human papillomavirus 16, 18 in women aged 18-45 years in Funing, Jiangsu province].. PubMed. 37(3). 406–9.
14.
Li, Jingxin, Lihua Hou, Fanyue Meng, et al.. (2016). Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial. The Lancet Global Health. 5(3). e324–e334.
15.
Wu, Ting, Yuemei Hu, Juan Li, et al.. (2015). Immunogenicity and safety of an E. coli-produced bivalent human papillomavirus (type 16 and 18) vaccine: A randomized controlled phase 2 clinical trial. Vaccine. 33(32). 3940–3946.
16.
Zhu, Fengcai, Lihua Hou, Jingxin Li, et al.. (2015). Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial. The Lancet. 385(9984). 2272–2279.
17.
Hu, Yuemei, Shoujie Huang, Kai Chu, et al.. (2013). Safety of anEscherichia coli-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine. Human Vaccines & Immunotherapeutics. 10(2). 469–475.
18.
Zhu, Fengcai, Zhenglun Liang, Fanyue Meng, et al.. (2012). Retrospective Study of the Incidence of HFMD and Seroepidemiology of Antibodies against EV71 and CoxA16 in Prenatal Women and Their Infants. PLoS ONE. 7(5). e37206–e37206.
19.
Meng, Rui, et al.. (2009). The epidemiological study on cryptosporidiosis in outpatients of Nanjing children's hospital.. Journal of Tropical Medicine. 9(4). 382–391.
20.
Liu, Yun, et al.. (2009). Sensitivity of SYBR Green real-time copro-PCR on detection of Schistosoma japonicum infection.. Journal of Pathogen Biology. 4(6). 432–435.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Weidong Yin Breakdown of academic impact, for papers by Nasamon Wanlapakorn Breakdown of academic impact, for papers by Yuansheng Hu Breakdown of academic impact, for papers by Penny M. Heaton Breakdown of academic impact, for papers by Edward P K Parker Breakdown of academic impact, for papers by Yoon‐Seok Chung Breakdown of academic impact, for papers by Irja Davidkin Breakdown of academic impact, for papers by Steven G. F. Wassilak Breakdown of academic impact, for papers by Lin Cui Breakdown of academic impact, for papers by Steven G.F. Wassilak